BTBP plans to abandon the acquisition of PLBIO business opportunity
I'm PortAI, I can summarize articles.
BTBP announced the abandonment of the acquisition opportunity for PLBIO, as the blood product business involved in the transaction poses a competitive conflict with its main business. The controlling shareholder China National Biological has formally notified BTBP in writing about this business opportunity based on the commitment letter to avoid competition. In the future, China National Biological will implement the acquisition of PLBIO from the perspective of overall development strategy and will make further commitments regarding the issue of competition after completion
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments